Experimental Narcolepsy Drug Shows Positive Wakefulness Results for Alkermes
ALKS sits 75% above its 52-week low of $25.165.
Summary
Alkermes announced positive trial results for an experimental drug, demonstrating improved wakefulness and reduced daytime sleepiness in patients with narcolepsy. This adds to a series of positive drug development news for the company, following positive Phase 3 results for LUMRYZ in narcolepsy in May and Orphan Drug Designations for alixorexton in June. Positive clinical data for a new drug candidate in a significant therapeutic area like narcolepsy can materially enhance the company's pipeline value and future revenue potential.
At the time of this announcement, ALKS was trading at $44.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4B. The 52-week trading range was $25.17 to $45.76. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Binance News.